. Author manuscript; available in PMC: 2010 Apr 1.

Published in final edited form as: Future Oncol. 2009 Jun;5(5):591–600. doi: 10.2217/fon.09.35

Table 1.

National Comprehensive Cancer Network acceptable drugs in recurrent epithelial ovarian carcinoma.

	Cytotoxic therapy	Hormonal therapy	Targeted therapy
Preferred agents	Cisplatin (if platinum-sensitive)	–	–
	Carboplatin (if platinum-sensitive)
	Gemcitabine
	Carboplatin/paclitaxel (category 1)
	(if platinum-sensitive)
	Gemcitabine/carboplatin
	Liposomal doxorubicin
	Topotecan

Other potentially active agents	Altretamine	Anastrozole	Bevacizumab
Other potentially active agents	Capecitabine	Letrozole
	Cyclophosphamide	Tamoxifen
	Docetaxel
	Etoposide, oral
	Ifosfamide
	Irinotecan
	Melphalan
	Oxaliplatin
	Paclitaxel
	Vinorelbine

Data taken from [6].